Ginkgo Datapoints, Tangible Scientific, and Inductive Bio Partner to Deploy AI-driven Lab-in-the-loop Workflows Across the Biopharma Industry

Rhea-AI Summary

Ginkgo Bioworks (NYSE: DNA) has announced a strategic partnership with Inductive Bio and Tangible Scientific to revolutionize AI-driven drug discovery workflows. The collaboration integrates three key capabilities: Ginkgo Datapoints' ADME profiling, Inductive Bio's chemistry design platform, and Tangible Scientific's compound management system.

The partnership aims to streamline the drug discovery process by combining high-throughput experimental workflows, compound management, and AI models into a unified service. Located in Boston's biopharma hub, the integrated platform offers rapid ADME profiling services including microsomal stability, kinetic solubility, P450 inhibition, and permeability testing, with optional in vitro toxicity assessments.

This collaboration supports the FDA's initiatives for faster development timelines, onshored services, increased AI tool usage, and adoption of non-animal preclinical testing approaches. The services are currently available for pharmaceutical and biotech teams.

Positive

• Integration of three complementary drug discovery platforms to reduce development time and costs
• Strategic location in Boston's biopharma hub enabling faster US-based logistics
• Alignment with FDA's initiatives for faster development and onshored services
• Real-time data integration and automated workflows reducing traditional bottlenecks

Negative

• None.

Insights

Biotechnology Industry Analyst

Ginkgo's new AI partnership strategically positions it in the lucrative drug discovery market with integrated workflow capabilities.

Ginkgo Bioworks is making a strategic move in the drug discovery space by partnering with Inductive Bio and Tangible Scientific to create an integrated AI-driven lab-in-the-loop service. This collaboration addresses a critical industry pain point: the fragmented, time-consuming process of drug discovery that typically involves shipping compounds between various global vendors, creating delays and coordination challenges.

The partnership combines three complementary capabilities: Ginkgo's ADME (Absorption, Distribution, Metabolism, Excretion) profiling, Inductive Bio's AI-powered chemistry design, and Tangible Scientific's compound management. Together, they create a seamless workflow from in-silico designs to validated experimental results—potentially reducing synthesis cycles, accelerating development timelines, and lowering costs.

This initiative aligns with FDA priorities for faster development timelines, domestic manufacturing, AI integration, and reduced animal testing. Strategically, Ginkgo is leveraging its Boston location as a competitive advantage, offering accelerated logistics to the biopharma hub. The company is positioning itself as an enabler of modern drug discovery, transforming from a synthetic biology platform into a more comprehensive partner for pharmaceutical companies.

While immediate revenue impact is unclear, this represents Ginkgo's continued expansion of service offerings beyond its core synthetic biology focus. For a company that has struggled with profitability, this partnership provides potential inroads into the lucrative $80+ billion drug discovery market, with opportunities for recurring revenue from pharmaceutical clients looking to modernize their discovery processes.

BOSTON, Aug. 20, 2025 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced that its Datapoints offering has entered into a new strategic partnership with Inductive Bio and Tangible Scientific to make AI-driven lab-in-the-loop drug discovery broadly accessible across the industry. The partnership aims to deliver capabilities that previously required massive platform investments by combining high-throughput experimental workflows, streamlined compound management, and predictive chemistry AI models into a seamless integrated service that could help scientists design better drugs with fewer resources.

The new collaboration connects three core capabilities: (1) Ginkgo Datapoints' rapid ADME profiling, (2) Inductive Bio's model–driven chemistry design platform, and (3) Tangible Scientific's API-enabled compound management platform. Together, these capabilities aim to move from in-silico compound designs to validated experimental results in one digitally-enabled workstream, with fewer synthesis cycles, faster turnarounds, and lower overall drug discovery costs.

Drug discovery has evolved far beyond the days when scientists would design, synthesize, and test compounds within a single facility. Today, the process is often a global logistics challenge — moving compounds across vendors and continents, introducing delays, and creating coordination bottlenecks. That fragmentation makes it harder to take advantage of AI-driven design and lab-in-the-loop workflows, where results are returned quickly integrated into models that inform the next design cycle.

"The image of scientists sketching molecules on a whiteboard and then walking down the hall to synthesize and test them is long outdated," said John Androsavich, General Manager at Ginkgo Datapoints. "By tightly coupling model-driven design with streamlined logistics to deliver AI/ML-ready assay data in real-time, we're making it easier for scientists to iterate quickly, take advantage of cutting edge digital tools, and focus on what they do best — discovering treatments for patients."

Lab-in-the-Loop Efficiency
Building on its announcement earlier this year of cost-competitive, fast-turnaround ADME services, Ginkgo is taking the next step in delivering innovative solutions in small molecule drug discovery through these partnerships. Ginkgo Datapoints' ADME profiling service delivers high-quality readouts — including microsomal stability, kinetic solubility, P450 inhibition, and permeability — with optional in vitro toxicity readouts on both lead candidates and library-scale compound sets. Ginkgo's services benefit from accelerated US-based logistics local to Boston's biopharma hub, in-house data infrastructure, and lab automation capabilities.

Tangible Scientific, also strategically located near Boston, orchestrates the secure storage, handling, and rapid movement of customer compounds, with delivery to local service providers including Ginkgo. The company's tech-enabled platform unifies compounds, data, and decision-making into a single, automated pipeline. Using Tangible's platform, researchers can submit orders for Ginkgo's ADME services directly from their digital environments, receive real-time status notifications, access structured, metadata-rich assay results in days, not weeks, and instantly integrate those results into downstream design workflows.

Inductive Bio's Compass platform allows chemists to explore and rank design ideas using fine-tuned ADMET prediction models trained on a broad consortium dataset. Designs can then be sent to Tangible and Ginkgo for experimental validation which are then fed back into the models, creating a lab-in-the-loop cycle that combines predictive accuracy with real-world results.

Practical Step Toward Faster Development
By aligning design, experiment, and data delivery into a single connected process, the partnership aims to reduce the time and uncertainty in early-stage drug development. It also supports the FDA's push for faster, more efficient development timelines, onshored manufacturing and services, greater use of AI tools, and adoption of non-animal approaches in preclinical testing.

Availability
The services are available now and are tailored for pharmaceutical and biotech teams looking to improve ADMET optimization and reduce iteration times on programs and across portfolios.

About Ginkgo Bioworks
Ginkgo Bioworks builds the tools that make biology easier to engineer for everyone. Ginkgo R&D Solutions delivers customizable R&D packages—such as protein engineering, nucleic acid design, and cell-free systems—giving partners a comprehensive way to accelerate innovation across therapeutics, diagnostics, & manufacturing. Ginkgo Automation sells modular, integrated laboratory automation so scientists can spend their days planning and analyzing experiments rather than pipetting in the lab. Ginkgo Datapoints uses Ginkgo's in-house automation to generate the large lab data sets to power your AI models. Ginkgo Biosecurity is building and deploying the next-generation infrastructure and technologies that global leaders need to predict, detect, and respond to a wide variety of biological threats. For more information, visit ginkgobioworks.com and ginkgobiosecurity.com, read our blog, or follow us on social media channels such as X (@Ginkgo and @Ginkgo_Biosec), Instagram (@GinkgoBioworks), Threads (@GinkgoBioworks), or LinkedIn.

About Tangible Scientific
Tangible Scientific's facility in Natick, MA, strategically located just outside Boston, is optimized for storing and managing customer assets with courier service to local providers, including Ginkgo. Through Tangible's platform, researchers can directly submit orders for Ginkgo's ADME services from their digital environments, receive real-time status notifications, and access structured, metadata-rich assay results in days, rather than weeks. This customer-first model eliminates the friction of traditional, fragmented operations, reducing errors, increasing speed, and freeing scientists to focus on discovery instead of internal and external coordination.

About Inductive Bio
Inductive Bio has developed a collaborative AI platform that dramatically accelerates compound optimization, a critical and time-consuming step in developing new therapeutics. By building a pre-competitive data consortium and state-of-the-art ML models designed to map the drivers of small molecule Absorption, Distribution, Metabolism, Excretion and Toxicity (ADMET), Inductive's platform allows scientists to optimize initial compounds into leads and development candidates faster and with a better balance of ADMET properties.

Forward-Looking Statements of Ginkgo Bioworks
This press release contains certain forward-looking statements within the meaning of the federal securities laws, including statements regarding the capabilities and potential success of the partnership and Ginkgo's cell programming platform. These forward-looking statements generally are identified by the words "believe," "can," "project," "potential," "expect," "anticipate," "estimate," "intend," "strategy," "future," "opportunity," "plan," "may," "should," "will," "would," "will be," "will continue," "will likely result," and similar expressions. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, including but not limited to: (i) our ability to realize near-term and long-term cost savings associated with our site consolidation plans, including the ability to terminate leases or find sub-lease tenants for unused facilities, (ii) volatility in the price of Ginkgo's securities due to a variety of factors, including changes in the competitive and highly regulated industries in which Ginkgo operates and plans to operate, variations in performance across competitors, and changes in laws and regulations affecting Ginkgo's business, (iii) the ability to implement business plans, forecasts, and other expectations, and to identify and realize additional business opportunities, including with respect to our solutions and tools offerings, (iv) the risk of downturns in demand for products using synthetic biology, (v) the uncertainty regarding the demand for passive monitoring programs and biosecurity services, (vi) changes to the biosecurity industry, including due to advancements in technology, emerging competition and evolution in industry demands, standards and regulations, (vii) the outcome of any pending or potential legal proceedings against Ginkgo, (viii) our ability to realize the expected benefits from and the success of our Foundry platform programs and Codebase assets, (ix) our ability to successfully develop engineered cells, bioprocesses, data packages or other deliverables, (x) the product development, production or manufacturing success of our customers, (xi) our exposure to the volatility and liquidity risks inherent in holding equity interests in other operating companies and other non-cash consideration we may receive for our services, (xii) the potential negative impact on our business of our restructuring or the failure to realize the anticipated savings associated therewith and (xiii) the uncertainty regarding government budgetary priorities and funding allocated to government agencies. The foregoing list of factors is not exhaustive. You should carefully consider the foregoing factors and the other risks and uncertainties described in the "Risk Factors" section of Ginkgo's annual report on Form 10-K filed with the U.S. Securities and Exchange Commission (the "SEC") on February 25, 2025 and other documents filed by Ginkgo from time to time with the SEC. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and Ginkgo assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. Ginkgo does not give any assurance that it will achieve its expectations.

GINKGO BIOWORKS INVESTOR CONTACT:
investors@ginkgobioworks.com

GINKGO BIOWORKS MEDIA CONTACT:
press@ginkgobioworks.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/ginkgo-datapoints-tangible-scientific-and-inductive-bio-partner-to-deploy-ai-driven-lab-in-the-loop-workflows-across-the-biopharma-industry-302533834.html

SOURCE Ginkgo Bioworks

FAQ

What is the strategic partnership announced by Ginkgo Bioworks (DNA)?

Ginkgo Bioworks announced a partnership with Inductive Bio and Tangible Scientific to deploy AI-driven lab-in-the-loop workflows for drug discovery, combining ADME profiling, chemistry design, and compound management capabilities.

What services does the Ginkgo Bioworks (DNA) partnership offer for drug discovery?

The partnership offers ADME profiling services including microsomal stability, kinetic solubility, P450 inhibition, and permeability testing, with optional in vitro toxicity assessments, all integrated with AI-driven design and compound management.

How does the Ginkgo Bioworks (DNA) partnership improve drug development efficiency?

The partnership improves efficiency by combining high-throughput workflows, streamlined compound management, and AI models into a single integrated service, reducing synthesis cycles and development times.

Where are Ginkgo Bioworks (DNA) partnership services located and available?

The services are based in Boston's biopharma hub with US-based logistics, and are currently available for pharmaceutical and biotech teams looking to improve ADMET optimization.

What FDA initiatives does the Ginkgo Bioworks (DNA) partnership support?

The partnership supports FDA initiatives for faster development timelines, onshored manufacturing and services, greater AI tool usage, and adoption of non-animal approaches in preclinical testing.